

Special Issue

New Drugs, Innovative Antimicrobial Approaches, and Optimized Dosages: Bridging Research and Clinical Practice

Message from the Guest Editors

Currently, there is a global lack of antimicrobials, both for multidrug-resistant (MDR) bacteria, especially among gram-negative bacilli, and for an important number of viruses. Among bacteria, the evolving appearance of new enzymes causing hydrolysis of the beta-lactam rings rapidly spreading from one to other countries causes difficult-to-treat infections regarding health-care-associated infections and community-acquired infections. Among viral infections, there are effective drugs mainly for chronic viral infections, such as those caused by HIV, HCV, and scarce acute infections such as influenza, COVID-19 and herpesvirus, but not for approximately 90% of viruses causing human infections. Thus, the need for new therapies is urgent. This Special Issue focuses on new drug development and other antimicrobial approaches against MDR bacteria and viruses without current treatment. We are mainly interested in innovative drugs, dosages, and approaches, and adjuvants to antibiotics molecules for MDR bacterial infections and new drug development for viral infections.

Guest Editors

Prof. Dr. Jerónimo Pachón
Dr. Rocío Álvarez-Marín
Dr. María E. Pachón-Ibáñez

Deadline for manuscript submissions

30 June 2026



Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/225202

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)





Antibiotics

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



[mdpi.com/journal/
antibiotics](https://mdpi.com/journal/antibiotics)



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of
Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)